Lord, Abbett & Co
TPTX

Lord, Abbett & Co’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Lord, Abbett & Co’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-77,915
Closed -$3.72M – 711
2021
Q4 		$3.72M Sell
77,915
-376,353
-83% -$16.8M 0.01% 568
2021
Q3 		$30.2M Sell
454,268
-13,154
-3% -$937K 0.07% 354
2021
Q2 		$36.5M Sell
467,422
-636,374
-58% -$47M 0.09% 319
2021
Q1 		$104M Sell
1,103,796
-214,502
-16% -$25.5M 0.27% 111
2020
Q4 		$161M Buy
1,318,298
+471,812
+56% +$51.7M 0.42% 50
2020
Q3 		$73.9M Buy
846,486
+23,743
+3% +$1.65M 0.24% 128
2020
Q2 		$53.1M Sell
822,743
-162,295
-16% -$9.36M 0.19% 171
2020
Q1 		$44M Buy
985,038
+306,486
+45% +$16.3M 0.19% 161
2019
Q4 		$42.3M Buy
678,552
+346,770
+105% +$16.5M 0.14% 229
2019
Q3 		$12.5M Buy
331,782
+29,036
+10% +$1.26M 0.04% 489
2019
Q2 		$12.3M Buy
+302,746
New +$10.8M 0.04% 516

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Lord, Abbett & Co's TPTX Position: Q1 2022 in Review

Lord, Abbett & Co sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 77,915 shares — an estimated $3.72M sold.

Lord, Abbett & Co first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $161M in Q4 2020. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Lord, Abbett & Co reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 77,915 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $3.72M.
  • Lord, Abbett & Co first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
  • Lord, Abbett & Co's Turning Point Therapeutics, Inc. Common Stock position peaked at $161M in Q4 2020.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Lord, Abbett & Co's 13F filing for Q1 2022, filed 13 May 2022.